Oppenheimer initiated coverage of Ocugen (OCGN) with an Outperform rating and $10 price target The firm views Ocugen as an emerging gene therapy leader in blinding ocular disorders. The company’s lead asset OCU400 is in Phase 3 for retinitis pigmentosa. A potential 2027 approval could provide near-term entry into a “sizable and poorly-met rare disease market opportunity,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen price target raised to $22 from $15 at Lucid Capital
- Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
- Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk‑Reward
- Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value
- Ocugen Seeks Court Validation of Charter Amendment Dispute